FDA approves Pfizer\'s Humira biosimilar Trazimera

FDA approves Pfizer's Humira biosimilar Trazimera

Patients in the US will now be able to access another biosimilar version of AbbVie’s Humira (adalimumab) with the FDA approval of Pfizer’s Trazimera in the treatment of human epidermal growth factor receptor-2 (HER2) overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

Data supplied with the application supported the similarity of Trazimera to its reference product, including clinical equivalence and no clinically meaningful differences between them.

read more

Original Article: FDA approves Pfizer's Humira biosimilar Trazimera

More From BioPortfolio on "FDA approves Pfizer's Humira biosimilar Trazimera"